Jul 24, 2023 / 12:30PM GMT
Operator
Good day, everyone, and welcome to the Pivotal AGAVE-201 Top Line Axatilimab Data Conference Call. Today's call is being recorded.
At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Sharon Klahre - Syndax Pharmaceuticals, Inc. - VP of IR & Communications
Thank you, operator. Welcome, and thank you all for joining us today. I'm Sharon Klahre, and with me this morning to provide a review of top line results from the pivotal AGAVE-201 of axatilimab in adult and pediatric patients with chronic graft-versus-host disease, following two or more prior lines of therapy, are Michael Metzger, Chief Executive Officer; and Dr. Niel Gallagher, President and Head of R&D. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; Dr. Anjali Ganguli; Chief Business Officer; and Keith Goldan, Chief Financial Officer.
This morning, we issued a joint press release with Incyte, reporting top line data for the pivotal AGAVE
Syndax Pharmaceuticals Inc To Host Axatilimab AGAVE-201 Topline Data Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot